AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04544358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAILAMOS©
Description: BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
Study NCT01951651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
Study NCT01951651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide
Description: Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
Study NCT03233113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure therapy
Description: Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, \& Whiteside, 20011; Antony, Craske, \& Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, \& Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider.
Study NCT03233113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, \& Whiteside, 20011; Antony, Craske, \& Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, \& Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider.
Study NCT03198819 — intervention group
Intervention type: DRUG
Intervention: Local Rifampisin and İnrtravenous cefotaxime
Study NCT01708317 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACASI
Description: Youth who participated in this study completed the ACASI -- they provided details about their sexual history, and the software program used their responses to create a recommendation for chlamydia/gonorrhea testing. The information obtained through the ACASI was integrated into the emergency department (ED) electronic medical record. ED physicians and nurses were able to review the information and order chlamydia/gonorrhea testing if needed.
Study NCT02407483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Visual Guidance
Description: Laparoscopic simulator training, tested with laser visual guidance
Study NCT00596960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
Study NCT00596960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
Study NCT03204318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40-mg tablet administered orally once daily.
Study NCT03204318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
Study NCT03204318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
Study NCT02407483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2 D vision
Description: Laparoscopic simulator training, tested without laser visual guidance
Study NCT03418025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo Exercise Together intervention
Study NCT02583581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring (MindWave by NeuroSky)
Description: EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
Study NCT02583581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring (EPOC by Emotiv)
Description: EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
Study NCT03029624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin
Description: Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
Study NCT03731533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WellStart
Description: 1. Five weekly automated text messages linked to an online article on health and wellness.~2. Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~3. Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~4. Three group (up to 20 participants) health coach online visits (60 minutes).~5. Two online group visits with a dietitian in groups of 10-12 participants.~6. Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes).
Study NCT03204318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
Study NCT03204318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relugolix placebo
Description: Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
Study NCT00241722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Study NCT00241722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04007263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via 30 minute infusion once daily for 5 days
Study NCT03307993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Description: Idalopirdine 60-120 mg daily dose
Study NCT03867396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CROS
Description: Advanced Bionics CROS
Study NCT03867396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid
Description: Advanced Bionics Naida hearing aid
Study NCT03867396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implant Alone
Description: No hearing device on contralateral ear
Study NCT02273648 — intervention group
Intervention type: DEVICE
Intervention: Drug Eluting Stent (DES)
Description: Percutaneous Coronary Intervention
Study NCT01987427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin + phentermine placebo
Description: lorcaserin 10 mg BID + phentermine placebo BID
Study NCT01987427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin + phentermine-HCl + phentermine placebo
Description: lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
Study NCT01987427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin + phentermine-HCl
Description: lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
Study NCT04007263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679 25 mg via 30 minute infusion once daily for 5 days
Study NCT00363636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galiximab in combination with rituximab
Description: Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
Study NCT00363636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab in combination with placebo
Description: Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
Study NCT03692559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: full aseptic dressing
Description: Replacement of the central venous catheters in the dressing process
Study NCT03418025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03418025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01187628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosrenol (Lanthanum Carbonate, BAY77-1931)
Description: Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
Study NCT03418025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03418025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT00577083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscopy
Description: Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
Study NCT00577083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cap-fitted colonoscopy
Description: Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
Study NCT01469468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
Study NCT01469468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
Study NCT00907283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: 15 mg/Kg/twice for 1 year
Study NCT04116710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-110 (viagenpumatucel-L)
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
Study NCT04116710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-130
Description: Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
Study NCT03159884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Study NCT00144586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4 weeks
Study NCT00473720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin
Description: Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
Study NCT00473720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
Study NCT01367769 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention in this study.
Study NCT00794196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program for antidepressant treatment
Description: The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
Study NCT01411878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing the Risk
Description: Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
Study NCT01411878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Love Notes
Description: The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, \& Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
Study NCT03706807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
Study NCT03706807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Stimulation
Description: A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
Study NCT02376166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade > 1 toxicities)
Study NCT02694419 — intervention group
Intervention type: DEVICE
Intervention: Doppler evaluation
Description: Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
Study NCT02254538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS
Study NCT02254538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 400
Study NCT02254538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEG 400
Study NCT03616314 — intervention group
Intervention type: DEVICE
Intervention: stepping verticalization plus functional electrical stimulation
Description: patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
Study NCT03616314 — intervention group
Intervention type: DEVICE
Intervention: stepping verticalization
Description: patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
Study NCT03678649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
Study NCT02941679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1202
Description: Hanmi Pharmaceutical. Co., Ltd.
Study NCT03616314 — intervention group
Intervention type: OTHER
Intervention: conventional physiotherapy
Description: patients are treated only with 60 minutes/day of conventional physiotherapy
Study NCT02769390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine 1 mcg/Kg
Description: Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
Study NCT02769390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine 2 mcg/ Kg
Description: Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
Study NCT02769390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine 3 mcg/ Kg
Description: Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
Study NCT04148508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Emotional Competence Self-help
Description: The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion. Interventions are personalised to the individual based on emotional competence skills. Intervention is in addition to self-monitoring in the app. Intervention components include selection of 2 from 4 of : targeting worry and rumination; increasing emotional knowledge and perception skills; improving achievement appraisals including attribution retraining and growth mindset; improving social appraisals including positive interpretations of ambiguous social events
Study NCT04148508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioural Approach
Description: The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion, based on cognitive-behavioural principles such as increased activity and challenging negative thinking. Interventions are generic and common to all participants. Intervention is in addition to self-monitoring in the app.
Study NCT04148508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
Study NCT04148508 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-monitoring
Description: Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
Study NCT04148508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
Study NCT04401995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidutolimod (CMP-001)
Description: A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
Study NCT04401995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.